Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glumetinib plus Osimertinib in EGFR TKI–resistant MET-amplified NSCLC (Ib/II)
CTR20191837Phase 2Terminated
- Sponsor
- Shanghai Institute of Materia Medica
- Start
- Sep 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of glumetinib, osimertinib in non-small cell lung cancer (NSCLC), sponsored by Shanghai Institute of Materia Medica. Started Sep 2019; status: terminated.
02
Drugs
glumetinibosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20191837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191837.